These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18589126)

  • 1. Patient outcomes and economics of once-daily tacrolimus in renal transplant patients: results of a modeling analysis.
    Abecassis MM; Seifeldin R; Riordan ME
    Transplant Proc; 2008 Jun; 40(5):1443-5. PubMed ID: 18589126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2015; 18(12):1050-9. PubMed ID: 26201252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplantation; 2007 Jun; 83(12):1648-51. PubMed ID: 17589351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring.
    Kuypers DR; Peeters PC; Sennesael JJ; Kianda MN; Vrijens B; Kristanto P; Dobbels F; Vanrenterghem Y; Kanaan N;
    Transplantation; 2013 Jan; 95(2):333-40. PubMed ID: 23263559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First clinical experience with the new once-daily formulation of tacrolimus.
    First MR
    Ther Drug Monit; 2008 Apr; 30(2):159-66. PubMed ID: 18367975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients.
    Florman S; Alloway R; Kalayoglu M; Punch J; Bak T; Melancon J; Klintmalm G; Busque S; Charlton M; Lake J; Dhadda S; Wisemandle K; Wirth M; Fitzsimmons W; Holman J; First MR
    Transplantation; 2007 Jun; 83(12):1639-42. PubMed ID: 17589349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2014 Jul; 17(7):520-6. PubMed ID: 24754700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature.
    Tran D; Vallée M; Collette S; Senécal L; Lafrance JP; Dandavino R; Boucher A
    Exp Clin Transplant; 2014 Aug; 12(4):323-7. PubMed ID: 24844288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):867-70. PubMed ID: 15848559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach.
    Jürgensen JS; Arns W; Hass B
    Eur J Health Econ; 2010 Feb; 11(1):15-25. PubMed ID: 19296139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients.
    Tinti F; Meçule A; Poli L; Bachetoni A; Umbro I; Brunini F; Barile M; Nofroni I; Berloco PB; Mitterhofer AP
    Transplant Proc; 2010 Dec; 42(10):4047-8. PubMed ID: 21168623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes.
    Orme ME; Jurewicz WA; Kumar N; McKechnie TL
    Pharmacoeconomics; 2003; 21(17):1263-76. PubMed ID: 14986738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient.
    Merli M; Di Menna S; Giusto M; Giannelli V; Lucidi C; Loria I; Ginanni Corradini S; Mennini G; Rossi M
    Transplant Proc; 2010 May; 42(4):1322-4. PubMed ID: 20534292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction.
    Shitrit D; Ollech JE; Ollech A; Bakal I; Saute M; Sahar G; Kramer MR
    J Heart Lung Transplant; 2005 Dec; 24(12):2148-52. PubMed ID: 16364864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing renal transplant patients' adherence to free cyclosporine and free tacrolimus immunosuppressant therapy.
    Chisholm MA; Mulloy LL; DiPiro JT
    Clin Transplant; 2005 Feb; 19(1):77-82. PubMed ID: 15659138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic tacrolimus (Pan Graf) in renal transplantation: an experience of 155 recipients in India.
    Guleria S; Kamboj M; Chatterjee A; Sharma M; Awasthy V; Dinda A; Mahajan S; Bhowmik D; Gupta S; Agarwal SK; Tiwari SC
    Transplant Proc; 2008 Sep; 40(7):2237-9. PubMed ID: 18790202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies.
    van Hooff JP; Alloway RR; Trunečka P; Mourad M
    Clin Transplant; 2011; 25(1):E1-12. PubMed ID: 21158926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure.
    Jevnikar A; Arlen D; Barrett B; Boucher A; Cardella C; Cockfield SM; Rush D; Paraskevas S; Shapiro J; Shoker A; Yilmaz S; Zaltzman JS; Kiberd B
    Transplantation; 2008 Oct; 86(7):953-60. PubMed ID: 18852662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreas transplant outcomes for United States (US) cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR).
    Gruessner AC; Sutherland DE
    Clin Transpl; 2008; ():45-56. PubMed ID: 19708445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.